Demand for radiotherapy will rise substantially over next 10 yearsApril 19, 2016
The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology .
These projections come from a new study by HERO, the Health Economics in Radiation Oncology project of the European Society for Radiotherapy and Oncology. The results will also be presented at the ESTRO 35 conference , to be held in Turin, Italy, from Friday 29 April - Tuesday 3 May 2016.
"Because radiotherapy involves significant outlay in equipment costs as well as in staff, long-term planning is necessary in order to achieve the required results. We, therefore, decided to try to forecast the radiotherapy needs of new cancer patients in the short to medium term in order to gain sufficient time for the purchase of appropriate machinery and the personnel training that will be required to meet this need," said Professor Yolande Lievens, from the Radiation Oncology Department, Ghent University Hospital, Ghent, Belgium, who is a co-author of the paper and president elect of ESTRO.
The research group, made up of senior radiation oncologists and epidemiologists from Belgium, Denmark, Spain, France and Australia, analysed European cancer incidence for the year 2013 by country and by tumour site, using data from the International Agency for Research on Cancer (IARC) GLOBOCAN project on worldwide cancer incidence and mortality.
Using statistical modelling, the researchers applied the 2012 country, sex and site incidence rates to the population forecast for 2025 in order to obtain projections of new cancer cases for that year. "Although these projections take demographic changes into account, we are unable to estimate the potential impact of changes in risk factors," co-author Professor Josep M. Borras, of the University of Barcelona, Spain, will tell the ESTRO35 conference on Sunday 1 May.
The detailed estimates for many different tumour sites produced some major increases. In breast, rectum, head and neck, lung and prostate tumours, which account for the highest percentage of patients in a radiotherapy department, there were relative increases of more than 25% in rectal patients for whom radiotherapy would be indicated in Spain, The Netherlands, and the Czech Republic, while Belgium, the UK, and Denmark had estimated increases of more than 20%.
Prostate cancer showed the highest expected increase over the period, with a 24.4% rise, followed by bladder cancer (21%) and multiple myeloma (20.4%), whereas projected increases in female breast cancer, lymphomas, and head and neck cancer were below average.
About four million new cancer patients are expected in Europe in 2025. This estimate is based on demographic changes, and represents a 15.9% increase on the 3.4 million diagnosed in 2012, assuming that overall cancer rates remain unchanged. Of these four million, the number of patients who would benefit from radiotherapy treatment at least once during the course of their disease would rise from approximately 1.7 million patients in 2012 to two million in 2025, which represents an increase of 16.1%.
This increase in new cancer cases is largely because the European population is ageing due to increased longevity and lower fertility levels. Indeed, the very old (80 years and over) now make up the fastest-growing population age group in Europe. Although migration also has an impact on demographic change, its impact is usually seen in younger age groups with a relatively lower cancer risk, the researchers say.
"Being able to estimate the number of new cancer patients requiring radiotherapy is essential if we are to be able to plan for radiotherapy services," said co-author Professor Cai Grau, from Aarhus University Hospital, Aarhus, Denmark. "We have shown clearly that the need for radiotherapy across Europe will increase substantially by the year 2025."
Professor Lievens said: "We hope that our study will focus the minds of European policymakers on the need to invest in radiotherapy, particularly as we know that there are already important differences in equipment and staff between European countries. This, taken together with the expected increase in the number of new cases of cancer, means that planning for the best possible treatment of patients needs to start now.
"ESTRO now intends to build a global partnership of organisations to help close the gap between the actual and the projected uptake of radiotherapy worldwide. A meeting to take this project forward will be held on Monday May 2 during the conference in Turin. We hope that we will able to play a major role in planning for and achieving the best possible situation for radiation oncology, and hence for patients, in the context of multidisciplinary cancer care in the future."
 "How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis", by Josep M. Borras, Yolande Lievens, Michael Barton, Julieta Corral, Jacques Ferlay, Freddie Bray, Cai Grau. Radiother Oncol (2016); http://dx.doi.org/10.1016/j.radonc.2016.02.016
 Abstract no: OC-0331, Proffered papers: Uncovering the gap between optimal and actual utilisation of radiotherapy in Europe, 16.15-17.15 hrs (CEST) on Sunday 1 May, Room 2.
ESTRO 35 is attended by about 5000 participants from 80 countries. It features new research results in clinical radiation oncology, radiobiology, physics, technology, and brachytherapy, presented by top doctors and scientists from all over the world.
European Society for Radiotherapy and Oncology (ESTRO)
Related Radiotherapy Current Events and Radiotherapy News Articles
Vismodegib in basal cell carcinoma: Added benefit not proven
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG).
Vitamin A may help improve pancreatic cancer chemotherapy
Around 8,800 people in the UK are diagnosed with pancreatic cancer each year. It is known as the UK's deadliest cancer, with a survival rate of just 3 per cent.
Gene therapy against brain cancer
Only a few days ago, the press (especially in English-speaking countries) enthusiastically announced the publication of a study that described in great detail the genetics of breast cancer, a discovery that according to many marks a breakthrough in the battle against this cancer.
Radiotherapy halves deaths from prostate cancer 15 years after diagnosis
A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death from prostate cancer 15 years after diagnosis.
A better way to diagnose and manage neuroendocrine tumors
A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors (NETS), and could significantly impact treatment management.
Improvements to online health information can help reduce barriers to care for pancreatic cancer
The Internet has become a powerful and important resource for daily life. When patients receive a medical diagnosis, particularly a difficult one like pancreatic cancer, the web can be an essential information tool, helping to enable patients to have meaningful discussions with health care providers.
Failure to publish trial results exposes patients to risks without providing benefits
Although the publication of results of clinical trials carried out in the USA within 12 months of their completion has been mandatory since 2007, an astoundingly high number of Phase III radiotherapy trials did not do so, according to new research to be presented at the ESTRO 35 conference today (Saturday).
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer (NSCLC) with a type of radiotherapy called stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer.
UT Southwestern research shows 98 percent cure rate for prostate cancer using SBRT
A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center.
Shortened RT schedule benefits low-risk prostate cancer patients
Of the more than 220,000 patients newly diagnosed with prostate cancer in 2015, the vast majority will have had early-stage disease at low risk for recurrence.
More Radiotherapy Current Events and Radiotherapy News Articles